INS and type 2 diabetes mellitus: The objective of this phase 3a, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) 5 trial was to demonstrate the superiority of once-weekly semaglutide (0.5 and 1.0 mg) vs placebo on glycemic control in patients with uncontrolled T2D on basal insulin therapy.